NANOBIOTIX S.A. SP.ADR (5NRA) - Net Assets
Based on the latest financial reports, NANOBIOTIX S.A. SP.ADR (5NRA) has net assets worth €-84.48 Million EUR (≈ $-98.77 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€67.76 Million ≈ $79.22 Million USD) and total liabilities (€152.24 Million ≈ $177.99 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read 5NRA total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-84.48 Million |
| % of Total Assets | -124.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
NANOBIOTIX S.A. SP.ADR - Net Assets Trend (2021–2025)
This chart illustrates how NANOBIOTIX S.A. SP.ADR's net assets have evolved over time, based on quarterly financial data. Also explore NANOBIOTIX S.A. SP.ADR asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for NANOBIOTIX S.A. SP.ADR (2021–2025)
The table below shows the annual net assets of NANOBIOTIX S.A. SP.ADR from 2021 to 2025. For live valuation and market cap data, see 5NRA stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-84.48 Million ≈ $-98.77 Million |
-28.58% |
| 2024-12-31 | €-65.70 Million ≈ $-76.81 Million |
-3463.07% |
| 2023-12-31 | €-1.84 Million ≈ $-2.16 Million |
+93.18% |
| 2022-12-31 | €-27.05 Million ≈ $-31.62 Million |
-200.95% |
| 2021-12-31 | €26.79 Million ≈ $31.32 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NANOBIOTIX S.A. SP.ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2304200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Total Equity | €-84.48 Million | 100.00% |
NANOBIOTIX S.A. SP.ADR Competitors by Market Cap
The table below lists competitors of NANOBIOTIX S.A. SP.ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cultural Investment Holdings Co Ltd
SHG:600715
|
$1.21 Billion |
|
Puuilo Oyj
HE:PUUILO
|
$1.21 Billion |
|
Malion New Materials Co Ltd
SHE:300586
|
$1.21 Billion |
|
China Harzone Industry Corp Ltd
SHE:300527
|
$1.21 Billion |
|
Power Solutions International, Inc. Common Stock
NASDAQ:PSIX
|
$1.21 Billion |
|
Betsson AB
ST:BETS-B
|
$1.21 Billion |
|
Rolls-Royce Holdings PLC
LSE:RR
|
$1.21 Billion |
|
Mahanagar Gas Limited
NSE:MGL
|
$1.21 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NANOBIOTIX S.A. SP.ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -65,703,000 to -84,483,000, a change of -18,780,000.
- Net loss of 23,961,000 reduced equity.
- New share issuances of 1,535,000 increased equity.
- Other factors increased equity by 3,646,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-23.96 Million | -28.36% |
| Share Issuances | €1.53 Million | +1.82% |
| Other Changes | €3.65 Million | +4.32% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares NANOBIOTIX S.A. SP.ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.77 | €27.40 | x |
| 2022-12-31 | €-0.78 | €27.40 | x |
| 2023-12-31 | €-0.04 | €27.40 | x |
| 2024-12-31 | €-1.39 | €27.40 | x |
| 2025-12-31 | €-1.75 | €27.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NANOBIOTIX S.A. SP.ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -80.83%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-35.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -175.44% | -470030.00% | 0.00x | 3.80x | €-49.68 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-54.34 Million |
| 2023 | 0.00% | -132.08% | 0.32x | 0.00x | €-39.52 Million |
| 2024 | 0.00% | 0.00% | -0.17x | 0.00x | €-61.56 Million |
| 2025 | 0.00% | -80.83% | 0.44x | 0.00x | €-15.51 Million |
Industry Comparison
This section compares NANOBIOTIX S.A. SP.ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,853,365,206
- Average return on equity (ROE) among peers: -33.32%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NANOBIOTIX S.A. SP.ADR (5NRA) | €-84.48 Million | -175.44% | N/A | $1.21 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $344.93 Million | -8.14% | 0.08x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $1.05 Billion | -42.40% | 0.17x | $2.05 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.73 Billion | -7.29% | 0.04x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $2.19 Million | -197.55% | 0.15x | $3.31 Million |
About NANOBIOTIX S.A. SP.ADR
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more